Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus

ASX, News,

Telix signs a commercial distribution agreement with BIOKOSMOS for prostate cancer investigational imaging product Illuccix® in Greek and Cypriot…

Read more

First Patient Dosed in ProstACT Program for Prostate Cancer Therapy

Clinical, News,

Telix announces that the first patient has been dosed in the Company’s PSMA-targeting ‘ProstACT’ therapeutic…

Read more

Telix Completes A$175 Million Placement and Launches A$25 Million SPP

ASX, News,

Telix announces a successful $175 million institutional placement and launches Share Purchase Plan to raise up to $25…

Read more

Activities Report and Appendix 4C for December 2021 Quarter

ASX, News,

Telix provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December…

Read more

Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study

Clinical, News,

Telix is pleased to announce a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or…

Read more

First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

Clinical, News,

Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder…

Read more

FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®

ASX, News,

Read more

TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021

Events, News,

Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab)…

Read more

Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain

ASX, News,

Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product,…

Read more

Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil

ASX, News,

The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging…

Read more
1 … 26 27 28 29 30 … 46

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings